POS0171 A STANDARDIZED ASSESSMENT OF TREATMENT AND OUTCOME OF NEWLY DIAGNOSED PATIENTS WITH JIA WITHIN THE PROKIND PROJECT – PATHWAYS FOR POLYARTICULAR JIA
Authors: S. Eulert, K. Vollbach, K. Tenbrock, J. Klotsche, D. Foell, J. P. Haas, F. Weller-Heinemann, S. Mrusek, P. Oommen, D. Windschall, K. Moenkemoeller, T. Kallinich, M. Hufnagel, I. Foeldvari, T. Hospach, M. Klaas, M. Rühlmann, R. Trauzeddel, N. Brueck, C. Schütz, J. B. Kuemmerle-Deschner, A. Klein, K. Minden, G. Horneff
Journal: Annals of the Rheumatic Diseases (2022)

Background The ProKind Commission of the Society for Paediatric and Adolescent Rheumatology (GKJR) has developed evidence- and consensus-based protocols for the diagnosis and therapy of children and adolescents with defined rheumatic diseases (e.g., [1]). In the ProKind-Rheuma project, it is now investigated whether the protocols are followed in everyday clinical practice and what the treatment-associated outcomes are. Objectives To investigate the mode of treatment and treatment response in patients with polyarticular juvenile idiopathic arthritis (pJIA). Methods ProKind-Rheuma is a multicenter prospective non-interventional observational study. Patients with pJIA enrolled until 17/1/2022 were included into this analysis. Treatments and outcomes up to the 3-month follow-up visit (3FU) were analyzed. Disease states were categorized based on the 2021 cJADAS10 cutoffs [2]. Results To date, 18 pediatric rheumatology facilities have participated in ProKind-Rheuma. Data from 203 patients with JIA are available. Of those, 44% have oligoarthritis, 36% polyarthritis, 9% systemic JIA, 6% enthesitis-related arthritis and 3% psoriatic arthritis. In total, 76 patients were diagnosed with pJIA, 38 with already completed 3FU: For 23 patients with pJIA and completed 3FU, we were able to analyze the protocol-defined [1] treatment goal of at least “minimal improvement”. In total, 18 (78%) achieved minimal improvement, 5 (22%) missed it. For 4 of those 5 patients, the underlying MTX therapy was escalated to a bDMARD (3 changed to MTX+bDMARD-combi, 1 to bDMARD-mono). In 3 other patients, therapy was also escalated to an MTX+bDMARD-combi. Between baseline and 3FU, 72% achieved cJADAS10-disease state improvement (Table 1) by at least one category (range 1 - 2), 0% decreased. Table 1. *based on non-missing values At Baseline all At Baseline with 3FU At 3FU Total 76 38 Female, n (%) 58 (76) 30 (79) Age (years), Mdn (IQR) 9 (3-12) 7 (2-12) 7.5 (3-12) Time since diagnosis (months), Mdn (IQR) 0 (0-1) 0 (0-1) 4 (3-4) RF-positivity, n (%) 8 (11) 3 (8) Number of active joints (arthritis), Mdn (IQR) 7 (4-12) 7 (5-12) 2 (0-4) JADAS10 (0-40), Mean (SD) (N BL+3FU = 23) 18.6 (7.4) 19.6 (7.6) 7.2 (4.2) cJADAS10 (0-30), Mean (SD) (N BL+3FU = 29) 16.3 (5.9) 16.7 (6.1) 7.1 (4.1) State of inactive disease (cJADAS10≤2.5), n (%*) 0 (0) 0 (0) 4 (13) State of minimal disease activity (2.5&lt;cJADAS10≤5), n (%*) 1 (2) 1 (3) 9 (28) State of moderate disease activity (5&lt;cJADAS10 ≤16), n (%*) 33 (54) 17 (50) 18 (56) State of high disease activity (cJADAS10&gt;16), n (%*) 27 (44) 16 (47) 1 (3) CHAQ (0-3), Mean (SD) 0.8 (0.8) 0.9 (0.8) 0.3 (0.5) Pain (NRS 0 - 10), Mean (SD) 4.3 (3) 4.7 (3) 2.2 (2.7) PedsQL 4.0 total score, Mean (SD) 66.3 (22.2) 65.4 (21.8) 78.4 (17.6) Intraarticular glucocorticoids &gt; 4 joints (ever), n (%) 12 (16) 5 (13) 7 (18) Glucocorticoid pulses (ever), n (%) 22 (29) 12 (32) 13 (34) Methotrexate, n (%) 56 (74) 31 (82) 34 (90) bDMARDs, n (%) 7 (9) 2 (5) 9 (24) Within the first 3 months after diagnosis, the treatment pathways proposed by the ProKind Commission [1] were followed in about three-quarters of patients: i) 5 (13%) received MTX and intra-articular glucocorticoid injections in more than 4 joints (IAGC), but no high-dose intravenous glucocorticoid pulse (HDGC) or bDMARD; ii) 8 (21%) received MTX and HDGC (no bDMARD, no IAGC); iii) 16 (42%) patients received MTX, of whom 4 received a bDMARD up to or at the 3FU (no HDGC, no IAGC). Nine (24%) patients were not treated with MTX or did not fit any of these categories, mostly due to starting bDMARD therapy in conjunction with HDGC or IAGC. Conclusion In the routine care of JIA patients with polyarthritis, the proposed treatment protocol and treat-to-target strategy are followed in most patients. At 3FU, improvements of JADAS10 and other outcomes were evident, with 41% having achieved inactive or minimal active disease. ProKind is funded by the Innovation Fund “Gemeinsamer Bundesausschuss”, FKZ: 01VSF18031 References [1]Horneff et al. Pediatric Rheumatology 2017; 15:78 [2]Trincianti et al. Arthritis Rheumatol. 2021 Nov; 73(11):1966-1975 Acknowledgements We are grateful to all physicians, medical professionals and everyone else who has so far contributed and supported the ProKind-Rheuma project. Moreover, we want to express special gratitude to all patients and their parents for their participation. Disclosure of Interests Sascha Eulert: None declared, Kristina Vollbach: None declared, Klaus Tenbrock: None declared, Jens Klotsche: None declared, Dirk Foell Speakers bureau: Speaker fees/honoraria from Boehringer, Novartis, Werfen and Sobi, Grant/research support from: Novartis and Sobi, Johannes-Peter Haas: None declared, Frank Weller-Heinemann: None declared, Sonja Mrusek: None declared, Prasad Oommen: None declared, Daniel Windschall Speakers bureau: Research support and speakers fee: Pfizer, Novartis, Abbvie, Medac, Sobi, Canon, Grant/research support from: Research support and speakers fee: Pfizer, Novartis, Abbvie, Medac, Sobi, Canon, Kirsten Moenkemoeller: None declared, Tilmann Kallinich: None declared, Markus Hufnagel: None declared, Ivan Foeldvari Consultant of: Addvisory board: Hexal, Novartis, Pfizer, Toni Hospach Consultant of: Advisory board: Sobi, Novartis, Moritz Klaas: None declared, Michael Rühlmann: None declared, Ralf Trauzeddel: None declared, Normi Brueck: None declared, Catharina Schütz: None declared, J. B. Kuemmerle-Deschner: None declared, Ariane Klein: None declared, Kirsten Minden Speakers bureau: Speaker: Pfizer, Novartis, Gerd Horneff: None declared